{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:11:14Z","timestamp":1788999074303,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76491-7","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:15:14Z","timestamp":1786547714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL-2 mutein-engrafted antibody MHS552 selectively expands functional regulatory T cells in nonclinical models and healthy participants"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-4867","authenticated-orcid":false,"given":"Igor","family":"Radanovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-7284","authenticated-orcid":false,"given":"Michael","family":"DiDonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-6531","authenticated-orcid":false,"given":"Anouk C.","family":"Meijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaiza","family":"Diaz-de-Durana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3038-4802","authenticated-orcid":false,"given":"Thierry","family":"Flandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Simonett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"McMullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9207-1807","authenticated-orcid":false,"given":"Manon AA.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Buters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3829-0037","authenticated-orcid":false,"given":"Mahdi","family":"Saghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"Gal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus J.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-0354","authenticated-orcid":false,"given":"Sjoerd H.","family":"van der Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Osanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Bagger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Calonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darbi","family":"Witmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-4328","authenticated-orcid":false,"given":"Frank","family":"Waldron-Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadege","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Kamphausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kistowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Marsot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Auger-Sarrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Rauld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Regairaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6973-5377","authenticated-orcid":false,"given":"Timothy","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi B.","family":"Klarenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8064-8426","authenticated-orcid":false,"given":"Matthijs","family":"Moerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-9090","authenticated-orcid":false,"given":"Robert","family":"Rissmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Spraggon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3529-1306","authenticated-orcid":false,"given":"Leona","family":"Gabry\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"76491_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar, M. & Hafler, D. A. Regulatory T cells in autoimmune disease. Nat. Immunol. 19, 665\u2013673 (2018).","journal-title":"Nat. Immunol."},{"key":"76491_CR2","doi-asserted-by":"crossref","unstructured":"Zhang, M. & Tang, Q. Manipulating IL-2 and IL-2R in autoimmune diseases and transplantation. Immunotherapy 7, 1231\u20131234 (2015).","DOI":"10.2217\/imt.15.94"},{"key":"76491_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1126\/science.1117893","volume":"310","author":"X Wang","year":"2005","unstructured":"Wang, X., Rickert, M. & Garcia, K. C. Structure of the Quaternary Complex of Interleukin-2 with Its \u03b1, \u03b2, and \u03b3c Receptors. Science 310, 1159\u20131163 (2005).","journal-title":"Science"},{"key":"76491_CR4","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1084\/jem.20060468","volume":"203","author":"N Seddiki","year":"2006","unstructured":"Seddiki, N. et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells.  J. Exp. Med. 203, 1693\u20131700 (2006).","journal-title":"J. Exp. Med."},{"key":"76491_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37424-w","volume":"14","author":"A Inaba","year":"2023","unstructured":"Inaba, A. et al. Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells. Nat. Commun. 14, 2071 (2023).","journal-title":"Nat. Commun."},{"key":"76491_CR6","doi-asserted-by":"publisher","unstructured":"Gra\u00dfhoff, H. et al. Low-dose IL-2 therapy in autoimmune and rheumatic diseases. Front. Immunol. 12, https:\/\/doi.org\/10.3389\/fimmu.2021.648408 (2021).","DOI":"10.3389\/fimmu.2021.648408"},{"key":"76491_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.2005.03.6830","volume":"24","author":"GC Cesana","year":"2006","unstructured":"Cesana, G. C. et al. Characterization of CD4 + CD25 + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24, 1169\u20131177 (2006).","journal-title":"J. Clin. Oncol."},{"key":"76491_CR8","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","volume":"107","author":"M Ahmadzadeh","year":"2006","unstructured":"Ahmadzadeh, M. & Rosenberg, S. A. IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients. Blood 107, 2409\u20132414 (2006).","journal-title":"Blood"},{"key":"76491_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00002371-200107000-00004","volume":"24","author":"DJ Schwartzentruber","year":"2001","unstructured":"Schwartzentruber, D. J. Guidelines for the safe administration of high-dose interleukin-2. J. Immunother. 24, 287\u2013293 (2001).","journal-title":"J. Immunother."},{"key":"76491_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrd.2018.148","volume":"17","author":"A Sharabi","year":"2018","unstructured":"Sharabi, A. et al. Regulatory T cells in the treatment of disease. Nat. Rev. Drug Discov. 17, 823\u2013844 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"76491_CR11","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055\u20132066 (2011).","journal-title":"N. Engl. J. Med."},{"key":"76491_CR12","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun, D. et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067\u20132077 (2011).","journal-title":"N. Engl. J. Med."},{"key":"76491_CR13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He, J. et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat. Med. 22, 991\u2013993 (2016).","journal-title":"Nat. Med."},{"key":"76491_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141\u2013149 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"76491_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41392-022-00887-2","volume":"7","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct. Target. Ther. 7, 67 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"76491_CR16","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s10753-023-01883-6","volume":"46","author":"Z Qiao","year":"2023","unstructured":"Qiao, Z. et al. Low-dose interleukin-2 for psoriasis therapy based on the regulation of Th17\/Treg cell balance in peripheral blood. Inflammation 46, 2359\u20132373 (2023).","journal-title":"Inflammation"},{"key":"76491_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209\u2013217 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"76491_CR18","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich, J. Y. et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann. Rheum. Dis. 81, 1685\u20131694 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"76491_CR19","doi-asserted-by":"crossref","unstructured":"Zhang, X. et al. Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial. Nat. Commun. 17, 5493 (2026).","DOI":"10.1038\/s41467-026-72245-7"},{"key":"76491_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43530-x","volume":"9","author":"SH Mahmoudpour","year":"2019","unstructured":"Mahmoudpour, S. H. et al. Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials. Sci. Rep. 9, 7145 (2019).","journal-title":"Sci. Rep."},{"key":"76491_CR21","doi-asserted-by":"publisher","first-page":"102844","DOI":"10.1016\/j.ebiom.2020.102844","volume":"59","author":"W Camu","year":"2020","unstructured":"Camu, W. et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. eBioMedicine 59, 102844 (2020).","journal-title":"eBioMedicine"},{"key":"76491_CR22","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","volume":"124","author":"F Van Gool","year":"2014","unstructured":"Van Gool, F. et al. Interleukin-5\u2013producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood 124, 3572\u20133576 (2014).","journal-title":"Blood"},{"key":"76491_CR23","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.4049\/jimmunol.1800907","volume":"201","author":"NC Ward","year":"2018","unstructured":"Ward, N. C. et al. IL-2\/CD25: A long-acting fusion protein that promotes immune tolerance by selectively targeting the IL-2 receptor on regulatory T cells.  J. Immunol. 201, 2579\u20132592 (2018).","journal-title":"J. Immunol."},{"key":"76491_CR24","unstructured":"Ptacin J. et al. THOR-809: An IL-2 Engineered from an expanded genetic alphabet for the potential treatment of autoimmune disorders. Arthritis Rheumatol. 71 https:\/\/acrabstracts.org\/abstract\/thor-809-an-il-2-engineered-from-an-expanded-genetic-alphabet-for-the-potential-treatment-of-autoimmune-disorders\/ (2019). Accessed 11 August, 2026."},{"key":"76491_CR25","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1136\/annrheumdis-2024-eular.618","volume":"83","author":"J Scheid","year":"2024","unstructured":"Scheid, J. et al. POS0899 First-in-human safety, pharmacokinetics, and pharmacodynamics data with MK-6194, a modified form of interleukin-2, designed to selectively activate regulatory T-cells \u2013 single ascending dose and multiple ascending dose trials. Ann. Rheum. Dis. 83, 1136\u20131137 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"76491_CR26","unstructured":"Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008). ClinicalTrials.gov NCT0545019 https:\/\/clinicaltrials.gov\/study\/NCT05450198 (2022). Accessed 10 August, 2026."},{"key":"76491_CR27","doi-asserted-by":"publisher","first-page":"1343.3","DOI":"10.1136\/annrheumdis-2022-eular.2244","volume":"81","author":"N Tchao","year":"2022","unstructured":"Tchao, N. et al. AB0432 Efavaleukin Alfa, a novel IL-2 mutein, selectively expands regulatory T cells in patients with Sle: final results of a phase 1b multiple ascending dose study. Ann. Rheum. Dis. 81, 1343.3\u20131344 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"76491_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2021-eular.2097","volume":"80","author":"J Visweswaraiah","year":"2021","unstructured":"Visweswaraiah, J. et al. Generation of PT101, a highly selective IL-2 mutein for treatment of autimmune diseases. Ann. Rheum. Dis. 80, 1\u201313 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"76491_CR29","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood.V130.Suppl_1.696.696","volume":"130","author":"N Tchao","year":"2017","unstructured":"Tchao, N. et al. Amg 592 is an investigational IL-2 mutein that induces highly selective expansion of regulatory T cells. Blood 130, 696\u2013696 (2017).","journal-title":"Blood"},{"key":"76491_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100103","volume":"4","author":"N Dixit","year":"2021","unstructured":"Dixit, N. et al. NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J. Transl. Autoimmun. 4, 100103 (2021).","journal-title":"J. Transl. Autoimmun."},{"key":"76491_CR31","first-page":"2715","volume":"69","author":"JL Langowski","year":"2017","unstructured":"Langowski, J. L. et al. NKTR-358: A selective, first-in-class IL-2 pathway agonist which increases number and suppressive function of regulatory T cells for the treatment of immune inflammatory disorders.  Arthritis Rheumatol. 69, 2715 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"76491_CR32","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","volume":"22","author":"R Hernandez","year":"2022","unstructured":"Hernandez, R., P\u00f5der, J., LaPorte, K. M. & Malek, T. R. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat. Rev. Immunol. 22, 614\u2013628 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"76491_CR33","doi-asserted-by":"publisher","first-page":"e83811","DOI":"10.1371\/journal.pone.0083811","volume":"8","author":"K Cerosaletti","year":"2013","unstructured":"Cerosaletti, K. et al. Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+CD25hi T cells of type 1 diabetic and multiple sclerosis patients. PLoS ONE 8, e83811 (2013).","journal-title":"PLoS ONE"},{"key":"76491_CR34","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.4049\/jimmunol.1100272","volume":"188","author":"G Garg","year":"2012","unstructured":"Garg, G. et al. Type 1 Diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4 + CD25 + regulatory T cell function.  J. Immunol. 188, 4644\u20134653 (2012).","journal-title":"J. Immunol."},{"key":"76491_CR35","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1172\/JCI78087","volume":"125","author":"VR Moulton","year":"2015","unstructured":"Moulton, V. R. & Tsokos, G. C. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J. Clin. Investig. 125, 2220\u20132227 (2015).","journal-title":"J. Clin. Investig."},{"key":"76491_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nm.3411","volume":"20","author":"F Carbone","year":"2014","unstructured":"Carbone, F. et al. Regulatory T cell proliferative potential is impaired in human autoimmune disease. Nat. Med. 20, 69\u201374 (2014).","journal-title":"Nat. Med."},{"key":"76491_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","volume":"36","author":"N Arenas-Ramirez","year":"2015","unstructured":"Arenas-Ramirez, N., Woytschak, J. & Boyman, O. Interleukin-2: biology, design and application. Trends Immunol. 36, 763\u2013777 (2015).","journal-title":"Trends Immunol."},{"key":"76491_CR38","doi-asserted-by":"crossref","unstructured":"DiDonato, M. et al. A novel interleukin-10 antibody graft to treat inflammatory bowel disease. Structure 33, 475\u2013488 (2025).","DOI":"10.1016\/j.str.2024.12.010"},{"key":"76491_CR39","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","volume":"10","author":"KO Saunders","year":"2019","unstructured":"Saunders, K. O. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front. Immunol. 10, 1296 (2019).","journal-title":"Front. Immunol."},{"key":"76491_CR40","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/j.1600-6143.2012.04133.x","volume":"12","author":"A Aoyama","year":"2012","unstructured":"Aoyama, A. et al. Low dose IL-2 for in vivo expansion of CD4+ and CD8+ regulatory T cells in nonhuman primates. Am. J. Transpl. 12, 2532\u20132537 (2012).","journal-title":"Am. J. Transpl."},{"key":"76491_CR41","doi-asserted-by":"publisher","first-page":"e003155","DOI":"10.1136\/jitc-2021-003155","volume":"10","author":"R Merchant","year":"2022","unstructured":"Merchant, R. et al. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate. J. Immunother. Cancer 10, e003155 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"76491_CR42","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni1263","volume":"6","author":"JD Fontenot","year":"2005","unstructured":"Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142\u20131151 (2005).","journal-title":"Nat. Immunol."},{"key":"76491_CR43","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.4049\/jimmunol.0903940","volume":"185","author":"L Barron","year":"2010","unstructured":"Barron, L. et al. Cutting edge: mechanisms of IL-2\u2013dependent maintenance of functional regulatory T cells.  J. Immunol. 185, 6426\u20136430 (2010).","journal-title":"J. Immunol."},{"key":"76491_CR44","unstructured":"Harada, Y. & Yahara, I. Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals. Int. Rev. Exp. Pathol. 34 Pt A, 37\u201355 (1993)."},{"key":"76491_CR45","first-page":"57","volume":"42","author":"GHI Wolfgang","year":"1998","unstructured":"Wolfgang, G. H. I., McCabe, R. D. & Johnson, D. E. Toxicity of Subcutaneously Administered Recombinant Human Interleukin-2 in Rats. Toxicol. Sci. 42, 57\u201363 (1998).","journal-title":"Toxicol. Sci."},{"key":"76491_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","volume":"26","author":"TR Malek","year":"2008","unstructured":"Malek, T. R. The biology of interleukin-2. Annu. Rev. Immunol. 26, 453\u2013479 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"76491_CR47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/019262339302100206","volume":"21","author":"TD Anderson","year":"1993","unstructured":"Anderson, T. D. Cytokine-induced changes in the leukon. Toxicol. Pathol. 21, 147\u2013157 (1993).","journal-title":"Toxicol. Pathol."},{"key":"76491_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100152","volume":"5","author":"C Fanton","year":"2022","unstructured":"Fanton, C. et al. Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus. J. Transl. Autoimmun. 5, 100152 (2022).","journal-title":"J. Transl. Autoimmun."},{"key":"76491_CR49","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.clindermatol.2020.06.008","volume":"38","author":"AR Cardones","year":"2020","unstructured":"Cardones, A. R. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clin. Dermatol. 38, 702\u2013711 (2020).","journal-title":"Clin. Dermatol."},{"key":"76491_CR50","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.jid.2018.10.048","volume":"139","author":"Y-G Tsai","year":"2019","unstructured":"Tsai, Y.-G. et al. Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptoms syndrome. J. Invest. Dermatol. 139, 1722\u20131731 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"76491_CR51","doi-asserted-by":"publisher","unstructured":"Gschwend, A. et al. Treatment with IL5-\/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS). Allergo J. Int. https:\/\/doi.org\/10.1007\/s40629-022-00224-7 (2022).","DOI":"10.1007\/s40629-022-00224-7"},{"key":"76491_CR52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jdermsci.2012.10.002","volume":"69","author":"K Ogawa","year":"2013","unstructured":"Ogawa, K. et al. Identification of thymus and activation-regulated chemokine (TARC\/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)\/drug rash with eosinophilia and systemic sym. J. Dermatol. Sci. 69, 38\u201343 (2013).","journal-title":"J. Dermatol. Sci."},{"key":"76491_CR53","first-page":"31","volume":"6","author":"S Choudhary","year":"2013","unstructured":"Choudhary, S., McLeod, M., Torchia, D. & Romanelli, P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J. Clin. Aesthet. Dermatol. 6, 31\u201337 (2013).","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"76491_CR54","unstructured":"Nektar Presents. New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at.  | Nektar Therapeutics https:\/\/ir.nektar.com\/news-releases\/news-release-details\/nektar-presents-new-data-rezolve-ad-phase-2b-study (2025)."},{"key":"76491_CR55","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/S2665-9913(19)30018-9","volume":"1","author":"JY Humrich","year":"2019","unstructured":"Humrich, J. Y. et al. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial.  Lancet Rheumatol. 1, e44\u2013e54 (2019).","journal-title":"Lancet Rheumatol."},{"key":"76491_CR56","doi-asserted-by":"crossref","unstructured":"Zhang, S.-X. et al. Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis. Ther. Ad. Musculoskelet. Dis. 13, 1759720X2110113 (2021).","DOI":"10.21203\/rs.3.rs-93717\/v1"},{"key":"76491_CR57","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.3390\/ijms21197015","volume":"21","author":"PJ Eggenhuizen","year":"2020","unstructured":"Eggenhuizen, P. J., Ng, B. H. & Ooi, J. D. Treg enhancing therapies to treat autoimmune diseases. Int. J. Mol. Sci. 21, 7015 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"76491_CR58","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10753-012-9496-8","volume":"35","author":"N Yu","year":"2012","unstructured":"Yu, N. et al. CD4+CD25+CD127low\/\u2212 T cells: A more specific treg population in human peripheral blood. Inflammation 35, 1773\u20131780 (2012).","journal-title":"Inflammation"},{"key":"76491_CR59","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2337\/dc12-0038","volume":"35","author":"N Marek-Trzonkowska","year":"2012","unstructured":"Marek-Trzonkowska, N. et al. Administration of CD4+CD25highCD127\u2212 regulatory T cells preserves \u03b2-cell function in type 1 diabetes in children. Diab. Care 35, 1817\u20131820 (2012).","journal-title":"Diab. Care"},{"key":"76491_CR60","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/pedi.12029","volume":"14","author":"N Marek-Trzonkowska","year":"2013","unstructured":"Marek-Trzonkowska, N., My\u015bliwec, M., Siebert, J. & Trzonkowski, P. Clinical application of regulatory T cells in type 1 diabetes. Pediatr. Diab. 14, 322\u2013332 (2013).","journal-title":"Pediatr. Diab."},{"key":"76491_CR61","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1126\/science.abp8243","volume":"376","author":"A Levescot","year":"2022","unstructured":"Levescot, A. & Cerf-Bensussan, N. Regulatory CD8 + T cells suppress disease. Science 376, 243\u2013244 (2022).","journal-title":"Science"},{"key":"76491_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53384-1","volume":"15","author":"JI Silverberg","year":"2024","unstructured":"Silverberg, J. I. et al. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nat. Commun. 15, 9230 (2024).","journal-title":"Nat. Commun."},{"key":"76491_CR63","unstructured":"Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus. https:\/\/www.prnewswire.com\/news-releases\/nektar-therapeutics-announces-phase-2-topline-data-for-rezpegaldesleukin-in-patients-with-systemic-lupus-erythematosus-301754953.html (2023)."},{"key":"76491_CR64","unstructured":"Amgen. Amgen Reports First Quarter Financial Results (Press release, 2023)."},{"key":"76491_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13027","volume":"7","author":"L P\u00e9rol","year":"2016","unstructured":"P\u00e9rol, L. et al. Loss of immune tolerance to IL-2 in type 1 diabetes. Nat. Commun. 7, 13027 (2016).","journal-title":"Nat. Commun."},{"key":"76491_CR66","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13075-015-0739-6","volume":"17","author":"HW van Steenbergen","year":"2015","unstructured":"van Steenbergen, H. W. et al. IL2RA is associated with persistence of rheumatoid arthritis. Arthritis Res. Ther. 17, 244 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"76491_CR67","doi-asserted-by":"publisher","first-page":"2363937","DOI":"10.1080\/07853890.2024.2363937","volume":"56","author":"S Du","year":"2024","unstructured":"Du, S. Zhao,Lili, Wu,Jiaming, Shi,Xiaofei & and Liu, R. FOXP3 gene polymorphisms increase the risk of systemic lupus erythematosus in a Han Chinese population. Ann. Med. 56, 2363937 (2024).","journal-title":"Ann. Med."},{"key":"76491_CR68","doi-asserted-by":"publisher","unstructured":"Tang, Y.-Y., Wang, D.-C., Chen, Y.-Y., Xu, W.-D. & Huang, A.-F. Th1-related transcription factors and cytokines in systemic lupus erythematosus. Front. Immunol. 14, https:\/\/doi.org\/10.3389\/fimmu.2023.1305590 (2023).","DOI":"10.3389\/fimmu.2023.1305590"},{"key":"76491_CR69","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner, B., Richter, W. & Schmidt, J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs 32, 425\u2013440 (2018).","journal-title":"BioDrugs"},{"key":"76491_CR70","unstructured":"Konrad, M. W. et al. Pharmacokinetics of recombinant interleukin-2 in humans. Cancer Research. 50, 2009\u20132017 (1990)."},{"key":"76491_CR71","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","volume":"167","author":"M S\u00e1nchez-F\u00e9lix","year":"2020","unstructured":"S\u00e1nchez-F\u00e9lix, M., Burke, M., Chen, H. H., Patterson, C. & Mittal, S. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge. Adv. Drug Deliv. Rev. 167, 66\u201377 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"76491_CR72","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.it.2025.02.010","volume":"46","author":"S Luo","year":"2025","unstructured":"Luo, S., Larson, J. H., Blazar, B. R., Abdi, R. & Bromberg, J. S. Foxp3+CD8+ regulatory T cells: bona fide Tregs with cytotoxic function. Trends Immunol. 46, 324\u2013337 (2025).","journal-title":"Trends Immunol."},{"key":"76491_CR73","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1084\/jem.20100209","volume":"207","author":"Y Grinberg-Bleyer","year":"2010","unstructured":"Grinberg-Bleyer, Y. et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207, 1871\u20131878 (2010).","journal-title":"J. Exp. Med."},{"key":"76491_CR74","doi-asserted-by":"publisher","unstructured":"P\u00f5der, J. et al. Durable control of autoimmunity requires sustained stimulation of regulatory T cells. Cell Rep. 45, https:\/\/doi.org\/10.1016\/j.celrep.2026.117292 (2026).","DOI":"10.1016\/j.celrep.2026.117292"},{"key":"76491_CR75","doi-asserted-by":"crossref","unstructured":"Li, Z., Li, D., Tsun, A. & Li, B. FOXP3+ regulatory T cells and their functional regulation. Cell. Mol. Immunol. 12, 558\u2013565 (2015).","DOI":"10.1038\/cmi.2015.10"},{"key":"76491_CR76","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/cei.12804","volume":"185","author":"AL Rodr\u00edguez-Perea","year":"2016","unstructured":"Rodr\u00edguez-Perea, A. L., Arcia, E. D., Rueda, C. M. & Velilla, P. A. Phenotypical characterization of regulatory T cells in humans and rodents. Clin. Exp. Immunol. 185, 281\u2013291 (2016).","journal-title":"Clin. Exp. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76491-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76491-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76491-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:03:28Z","timestamp":1788998608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76491-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76491"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76491-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors I.R., A.M., M.A.J., T.P.B., M.S., P.G., J.J.B., S.vd.B., S.O., N.B.K., M.M., and R.R. declare that they have no competing interests. All authors listed as affiliated with Novartis are full-time employees of the company, with C.S., N.H., U.S., H.M., J.M., A.A.S., M.K., A.K., D.A.S., C.eR., C.aR., C.C., and L.G. also owning company stock. Y.D., F.W.L., M.B., E.K., and N.P. were affiliated with Novartis at the time this work was conducted and Y.D. and N.P. own company stock.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9678"}}